Autoimmune pancreatitis secondary prevention

Autoimmune pancreatitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Autoimmune pancreatitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Guidelines for Management
Case Studies
Case #1
Autoimmune pancreatitis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Autoimmune pancreatitis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Autoimmune pancreatitis secondary prevention
CDC on Autoimmune pancreatitis secondary prevention
Autoimmune pancreatitis secondary prevention in the news
Blogs on Autoimmune pancreatitis secondary prevention
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Autoimmune pancreatitis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2]

Overview

Patients should be managed appropriately and timely with glucocorticoids and immunomodulatory drugs to prevent complications such as pancreatic insufficiency, diabetes, and pancreatic calcifications or stones.

Secondary Prevention

• Patients should be managed appropriately and timely with glucocorticoids and immunomodulatory drugs to prevent complications such as:
  • Pancreatic insufficiency
  • Diabetes
  • Pancreatic calcifications or stones